NCT00094055View on ClinicalTrials.gov

Study of the Anti-angiogenesis Agent AG-013736 in Patients With Metastatic Thyroid Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

September 30, 2004

Primary Completion Date

January 31, 2009

Study Completion Date

January 31, 2009

Conditions
Thyroid Neoplasms
Interventions
DRUG

AG013736

AG013736, tablets 5 mg BID daily until tumor progression or toxicity

Trial Locations (9)

19111

Pfizer Investigational Site, Philadelphia

48109

Pfizer Investigational Site, Ann Arbor

51231

Pfizer Investigational Site, Baltimore

60637

Pfizer Investigational Site, Chicago

80010

Pfizer Investigational Site, Aurora

80220

Pfizer Investigational Site, Denver

90404

Pfizer Investigational Site, Santa Monica

21231-1000

Pfizer Investigational Site, Baltimore

77030-4009

Pfizer Investigational Site, Houston

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY